Related Experiment Video
Updated: Oct 10, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors
1Department of Melanoma-Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. spatel@notes.mdacc.tmc.edu
Abstract:
The management of peritoneal and hepatic metastases from gastrointestinal stromal tumors is a challenging clinical problem. Currently available systemic therapeutic agents have very limited activity in this particular disease. Patients with disease confined to a single organ/region are therefore managed either by surgery or regional therapy e.g. intraperitoneal therapy or hepatic arterial chemoembolization, whereas those with multiple sites of involvement should be enrolled on experimental trials of new agents.
Insights
Managing peritoneal and hepatic metastases from gastrointestinal stromal tumors (GIST) is difficult. Systemic therapies are limited, favoring surgery or regional treatments for localized disease and clinical trials for widespread metastases.
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Surgical Oncology
Background:
- Peritoneal and hepatic metastases from gastrointestinal stromal tumors (GIST) present significant management challenges.
- Current systemic therapies demonstrate limited efficacy against these specific metastatic sites.
Purpose of the Study:
- To outline current management strategies for GIST with peritoneal and hepatic metastases.
- To differentiate treatment approaches based on the extent of disease involvement.
Main Methods:
- Review of existing literature and clinical guidelines for GIST metastasis management.
- Analysis of treatment outcomes for surgery, regional therapies, and systemic agents.
Main Results:
- Localized GIST metastases are often managed with surgical resection or regional therapies like intraperitoneal therapy or hepatic arterial chemoembolization.
- Patients with multifocal or widespread metastases are typically directed towards experimental clinical trials for novel therapeutic agents.
Conclusions:
- Treatment decisions for GIST metastases must be tailored to the specific site and extent of disease.
- A multidisciplinary approach integrating surgery, regional therapies, and investigational systemic agents is crucial for optimizing patient outcomes.
